Why the study?
Do biodegradable polymer or polymer-free rapamycin-eluting stents reduce target lesion revascularisation or improve safety compared to permanent polymer stents in patients with de novo coronary lesions?
Do biodegradable polymer or polymer-free rapamycin-eluting stents reduce target lesion revascularisation or improve safety compared to permanent polymer stents in patients with de novo coronary lesions?
Biodegradable polymer and polymer-free rapamycin-eluting stents demonstrate similar 2-year clinical efficacy and safety compared to permanent polymer stents.
No takes yet. Share an insight, caveat, or question.
No preference warranted among stent types for TLR or safety; confirms comparable 2-year efficacy across polymer platforms in de novo lesions.
Byrne et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: